Veriti Management LLC Biomarin Pharmaceutical Inc Transaction History

Veriti Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 13, 2023	SELL	$86.68 - $100.3 $77,058 - $89,166	-889 Reduced 15.14%	4,984 $432,000
Q1 2023 Apr 26, 2023	BUY	$87.74 - $117.27 $11,581 - $15,479	132 Added 2.3%	5,873 $571,000
Q4 2022 Jan 20, 2023	BUY	$80.93 - $108.63 $66,362 - $89,076	820 Added 16.66%	5,741 $0
Q3 2022 Oct 26, 2022	BUY	$82.16 - $96.94 $7,476 - $8,821	91 Added 1.88%	4,921 $417,000
Q2 2022 Jul 18, 2022	BUY	$71.48 - $86.85 $39,957 - $48,549	559 Added 13.09%	4,830 $400,000
Q1 2022 Apr 11, 2022	BUY	$74.28 - $92.69 $21,541 - $26,880	290 Added 7.28%	4,271 $329,000
Q4 2021 Jan 19, 2022	BUY	$71.72 - $91.47 $10,973 - $13,994	153 Added 4.0%	3,981 $352,000
Q3 2021 Oct 08, 2021	BUY	$74.77 - $85.47 $65,348 - $74,700	874 Added 29.59%	3,828 $296,000
Q2 2021 Jul 13, 2021	BUY	$75.51 - $84.79 $223,056 - $250,469	2,954 New	2,954 $246,000
Q1 2021 Apr 14, 2021	SELL	$74.73 - $90.69 $138,175 - $167,685	-1,849 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$72.61 - $90.2 $134,255 - $166,779	1,849 New	1,849 $162,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Veriti Management LLC, based on Form 13F filings with the SEC.

Stay updated on Veriti Management LLC with notifications on news.